Heart disease is a leading cause of death worldwide. But significant disparities exist in the incidence and severity of heart disease, particularly between men and women, and major barriers remain for the successful long-term care of heart disease patients.
Now, thanks to a $12-million Program Project Grant (PPG) from the National Heart, Lung, and Blood Institute, scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) are set to break down these barriers by exploring molecular mechanisms of heart injury and repair.
Ultimately, they hope to identify new paths to the development of innovative heart therapies.
The Principal Investigator on the new award is Walter J. Koch, PhD, W.W. Smith Endowed Chair in Cardiovascular Medicine, Professor and Chair of the Department of Pharmacology, and Director of the Center for Translational Medicine at LKSOM.
We are very excited about the new PPG. It gives us an exciting opportunity to discover more about the molecular basis of heart disease and, more specifically, heart failure, which affects more than six million people in the United States alone."
Walter J. Koch, PhD, W.W. Smith Endowed Chair in Cardiovascular Medicine
Advances in treatments for heart disease over the course of the last decade have significantly improved patient survival.
But mortality from heart failure, a major form of heart disease, remains high - about 40 percent of heart failure patients die within five years of diagnosis. In addition, little is known about why men experience more rapid heart failure progression than women.
"The persistently high rate of mortality in heart failure has created a significant need to learn more about mechanisms underlying tissue injury and tissue repair processes in the heart," Dr. Koch said.
To explore these aspects of heart disease, Dr. Koch and Center for Translational Medicine colleagues Raj Kishore, PhD, Professor of Pharmacology and Medicine and Director of the Center's Stem Cell Therapy Program; Douglas Tilley, PhD, Associate Professor of Pharmacology; and John Elrod, PhD, Associate Professor of Pharmacology and Associate Professor at the Alzheimer's Center at Temple, designed four distinct yet complementary and highly collaborative projects.
Dr. Koch's team will examine the role of molecules known as G protein-coupled receptor kinases (GRKs) in heart function and disease.
Part of this project is aimed at identifying the role specifically of GRK5 in heart failure. The team will also investigate whether limiting GRK5 activity can reduce tissue remodeling that occurs in the failing heart.
Dr. Kishore's portion of the research is focused on understanding the influence of gender on the ability of bone marrow stem cells to repair heart tissue.
In particular, his team will test the hypothesis that female-derived stem cells possess superior reparative properties compared to their male counterparts and that functional superiority of female stem cells involves both hormone-dependent and hormone-independent mechanisms.
"Whether there is a gender basis for differences in stem cell function in the repair of the injured heart - particularly a molecular basis for superior functionality of female-derived stem cells - is not known," Dr. Kishore said.
The third project, headed by Dr. Tilley, will explore the development of renal dysfunction during heart failure. "Renal dysfunction, in the form of cardiorenal syndrome (CRS), is a predictor for poor prognosis in heart failure patients," Dr. Tilley said. "A key indicator of CRS is renal fibrosis, which impairs proper kidney function, and prevention of which may help ameliorate heart failure."
Dr. Tilley and colleagues aim to define the role of immune cells known as leukocytes in mediating renal fibrosis in heart failure. Leukocytes regulate tissue fibrosis and are recruited to the kidney in various disease states.
Working with co-investigator Meredith Brisco-Bacik, MD, MSCE, FACC, Associate Professor of Medicine and Clinical Sciences at LKSOM, Dr. Tilley's team will further examine molecular profiles of leukocytes collected from the blood of patients with or without CRS.
"We are excited to work with Drs. Koch, Kishore, and Elrod to examine facets of leukocyte biology, including alterations in leukocyte-specific GRK expression and signaling, sex-based differences in leukocyte behavior, and alterations in leukocyte bioenergetics, to determine their impact on CRS progression and outcomes," Dr. Tilley added.
Dr. Elrod will lead the fourth project, which follows on his laboratory's discovery that targeting the process of calcium exchange in mitochondria (the energy-supplying powerhouses of cells) is an effective strategy to reduce tissue injury associated with heart attack.
His team is especially interested in understanding the role of a molecule known as MCUB in the regulation of mitochondrial calcium transport in heart failure. These studies could uncover ways to therapeutically reduce mitochondrial dysfunction in heart tissue.
The new award, completely housed in the Center for Translational Medicine at Temple, also funds one administrative and two scientific cores, one directed by Dr. Koch and the others led by Erhe Gao, MD, PhD, Professor in the Center for Translational Medicine and Sudarsan Rajan, PhD, Assistant Professor in the Center.
"This award is a testament to what we have built here at Temple and the Center for Translational Medicine under Dr. Koch's impeccable leadership," Dr. Kishore noted. "The scientific depth of these multi-component studies is quite exciting and is likely to open up new understanding of and potentially new therapeutic avenues for heart disease."
"Historically, a department or center that is funded by the PPG mechanism has been viewed as preeminent in their field and highly successful," Dr. Elrod added. "The fact that this is the second currently funded PPG emanating from the Center for Translational Medicine speaks volumes to the collaborative nature and scientific impact of our group as a whole."
View post:
- Stem Cell Therapy Market Types, Applications, Share, Growth - openPR - February 6th, 2025
- Placental Stem Cell Therapy Solution Market Size And Booming - openPR - February 6th, 2025
- Revitalizing Health with Stem Cell Therapy: A Groundbreaking Path To Longevity and Wellness - openPR - February 4th, 2025
- Gene therapy offers new hope for sickle cell disease patients - Open Access Government - February 4th, 2025
- Scientists trial implant to patch up the heart - BBC.com - February 2nd, 2025
- Cell Therapy Market Size is Projected to Reach USD 33.93 - GlobeNewswire - January 28th, 2025
- Meet the California Institute Pushing Stem Cell & Gene Therapy Research: Part 3 - The Medicine Maker - January 28th, 2025
- Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium 2025 - The Eastern... - January 28th, 2025
- Beyond the Lab: Stem cell research - Drug Target Review - January 25th, 2025
- Asia Pacific Stem Cell Therapy Market to Reach US$ 4,075.75 Million by 2033 with a Robust CAGR of 10.29% - openPR - January 25th, 2025
- Exciting data: S.Biomedics preps US IND of PD cell therapy - BioWorld Online - January 25th, 2025
- $24.85 Billion Cell Therapy Market Forecast by 2032 (CAGR 20.4%) - openPR - January 25th, 2025
- Stem Cell Therapy Market Expected to Expand at a Steady 2025-2032 - openPR - January 25th, 2025
- Regenerative Medicine Market to receive overwhelming hike US$ 164.9 billion in Revenues by 2032, Growing at a CAGR of 23.30% From 2024 to 2032 -... - January 25th, 2025
- Alternative medicine fans see RFK Jr. as a hero. The fields skeptics worry. - The Washington Post - January 23rd, 2025
- U.S. PRP and Stem Cell Alopecia Treatment Market Analysis 2025-2030 by Treatment, Indication, and End-use - Androgenic Alopecia Dominated the Market... - January 23rd, 2025
- The Future of Regenerative Medicine Lies in the Hands of Chiropractors - Dynamic Chiropractic - January 23rd, 2025
- Stem Cell Therapy Industry Dynamics and Contributions by RTI - openPR - January 21st, 2025
- Stem Cells Market to Reach USD 44.27 Billion by 2033, Driven by Expanding Applications and Innovations - openPR - January 21st, 2025
- Organoids at the Forefront Innovations in Stem Cell Research and Precision Medicine - openPR - January 21st, 2025
- The promising future of regenerative medicine - Yahoo Finance - January 17th, 2025
- An earful of gill: USC Stem Cell study points to the evolutionary origin of the mammalian outer ear - EurekAlert - January 11th, 2025
- Aspen Partners with Mytos to Automate Stem Cell Production for Parkinsons Therapy - Genetic Engineering & Biotechnology News - January 9th, 2025
- School of Medicine professor receives grant to study improved cancer treatments - Mercer University - January 9th, 2025
- Meet CIRM: the California Institute Pushing Stem Cell and Gene Therapy Research: Part 1 - The Medicine Maker - January 7th, 2025
- Regenerative Medicine Market to Experience Significant Growth, Projected to Reach $183.08 Billion by 2031. - openPR - January 7th, 2025
- Stem-cell therapies that work: 10 Breakthrough Technologies 2025 - MIT Technology Review - January 5th, 2025
- 1st stem cell therapy, new HIV drug approved - ecns - January 5th, 2025
- Science fiction turned reality? Stem cell therapy set to repair child's heart - Ynetnews - January 3rd, 2025
- Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology - The Manila Times - January 1st, 2025
- Allogeneic Stem Cell Transplantation Market Size to Expand Lucratively by 2031 - openPR - January 1st, 2025
- Apoptotic clearance by stem cells: molecular mechanisms for recognition and phagocytosis of dead cells - Nature.com - December 30th, 2024
- Why Medical Tourists are Choosing Mexico: The Affordable Alternative for Advanced Stem Cell Treatments - openPR - December 30th, 2024
- Induced Pluripotent Stem Cells (iPSC) Production Market: Trends, Growth, and the Role of AI - openPR - December 30th, 2024
- Stem cells 'instructed' to form specific tissues and organs - New Atlas - December 28th, 2024
- Stem Cell Transplantation Still the Main Treatment Option for Beta-Thalassemia - Medpage Today - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Galveston County Daily News - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Voice Of Alexandria - December 28th, 2024
- U.S. Stem Cell Therapy Market Revenue to Attain USD 17.70 Bn by 2033 - Precedence Research - December 27th, 2024
- Here are some biggest medical breakthroughs of 2024 - Medical Buyer - December 27th, 2024
- Researchers from Korea University explore how ascorbic acid and FGF4 revolutionize regenerative medicine - EurekAlert - December 27th, 2024
- Regenerative Medicine Market to Skyrocket to USD 73,084.2 Million by 2033 at a 18.5% of CAGR - openPR - December 27th, 2024
- Stem cell therapy to correct heart failure in children could 'transform lives' - Fox News - December 25th, 2024
- Advancing type 1 diabetes therapy: autologous islet transplant breakthrough - Nature.com - December 25th, 2024
- Stem Cell Therapy Market to Triple in Value, Reaching USD 52.1 Billion by 2034 at a 12.1% of CAGR - openPR - December 25th, 2024
- Stem-cell therapies: A breakthrough in treating parkinson's, cancer, diabetes, and more - The Business Standard - December 25th, 2024
- Replay 2024 : 6 Biggest Medical Breakthroughs Of 2024 - NewsX - December 25th, 2024
- Tumbling stem cells? Watch how movement plays a part in their fate - Scope - December 20th, 2024
- SCD patients free of VOEs after treatment with gene-editing therapy - Sickle Cell Disease News - December 20th, 2024
- Japan's Sumitomo to establish regenerative medicine and cell therapy joint venture - BSA bureau - December 20th, 2024
- Brain cells remain healthy after a month on the International Space Station, but mature faster than brain cells on Earth - EurekAlert - December 19th, 2024
- Reindeers Pave the Way for Regenerative Medicine - The Scientist - December 19th, 2024
- Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult... - December 19th, 2024
- What Role Does Regenerative Medicine Play In The Management Of Type 1 And Type 2 Diabetes? - TheHealthSite - December 19th, 2024
- World's 1st Stem Cell Book on Animals, Reveals How to Extend the Lives of Pets - PR Newswire - December 17th, 2024
- Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells - Business Wire - December 17th, 2024
- Stem Cells: Hope on the Horizon for Preterm Babies - Monash University - December 17th, 2024
- Stem Cell Transplant Offers No Difference in OS or PFS in Mantle Cell Lymphoma Compared with Maintenance Therapy Alone - OncoZine - December 17th, 2024
- Inside One Mans Journey with Multiple Myeloma - Men's Health - December 15th, 2024
- Stem Cells Market Size to Reach USD 48.83 Billion By 2034 - Exclusive Report by Precedence Research - BioSpace - December 13th, 2024
- Treating Heart Defects with Tissue-engineered Vascular Conduits - Yale School of Medicine - December 13th, 2024
- Tom Curry: England flanker has stem-cell therapy in bid to make 2027 World Cup - BBC.com - December 13th, 2024
- Stem Cell Manufacturing Market Dynamics Key Drivers Challenges and Technological Innovations - Set to reach USD 26.6 billion by 2033 - PharmiWeb.com - December 13th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of USD 54.7 Bn By 2033, At 12.6% CAGR: Dimension Market Research - The Manila Times - December 13th, 2024
- Stem cell transplantation could save the coral reefs - Ynetnews - December 13th, 2024
- Vitrification Market | Driving Innovations in Cryopreservation for Fertility Treatments and Regenerative - EIN News - December 13th, 2024
- Workshop on Regenerative Medicine concludes at SKUAST-K - Greater Kashmir - December 13th, 2024
- High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma - News-Medical.Net - December 11th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of - GlobeNewswire - December 11th, 2024
- Stem Cell Therapy Market to Worth Over US$ 2,612.92 Million By 2033 | Astute Analytica - GlobeNewswire - December 11th, 2024
- Changes in Blood Cell Production Over the Lifetime | Newswise - Newswise - December 7th, 2024
- Study reveals how stem cells respond to environmental signals, with implications for IBD and colorectal cancer - Medical Xpress - December 5th, 2024
- Stem cell therapy TED-A9 showing safety and early efficacy in trial - Parkinson's News Today - December 5th, 2024
- BMP-2 loaded scaffold for stem and immune cell recruitment in therapeutic applications - News-Medical.Net - December 5th, 2024
- Stem Cell Treatment May Help To Cure Vision Loss - Anti Aging News - December 5th, 2024
- BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024... - December 3rd, 2024
- Stem Cell Therapy Strategic Business Report 2024 - - GlobeNewswire - December 3rd, 2024
- Enhancing the efficacy of cell transplantation therapy for stroke or traumatic brain injury - Medical Xpress - December 1st, 2024
- Apheresis in Cellular Therapies: Unlocking Quality for CAR T and Stem Cell Treatments, Upcoming Webinar Hosted by Xtalks - PR Web - November 29th, 2024
- Stem Cell Therapy Market is expected to Double Its Size by Upcoming Decade - openPR - November 29th, 2024
Recent Comments